Peptide
Reference library
Educational peptide reference — research use only.
Research & educational use only
For laboratory and educational research only. Not for human or veterinary consumption. This is not medical advice. Always follow applicable laws and consult qualified professionals.
The calculator performs unit math for research reference. It must not be used to plan or guide dosing in humans or animals. Verify all figures independently in your lab protocol.
VIP
A neuropeptide studied in inflammation, motility, and circadian research.
- Half-life (approx.)
- ~1 min (approx., IV); very short
- Diluent
- Bacteriostatic water (0.9% benzyl alcohol)
- Common vials
- 5, 10 mg
Half-life figures are literature approximations for educational reference — not pharmacokinetic advice.
Overview
VIP (vasoactive intestinal peptide) is a 28-amino-acid neuropeptide studied in inflammation, pulmonary hypertension, and circadian regulation. It acts on VPAC1/VPAC2 receptors with broad immunomodulatory and smooth-muscle effects in research models. 28-mer neuropeptide with broad VPAC1/VPAC2 anti-inflammatory and smooth-muscle effects.
Structure & identity
28-mer vasoactive intestinal peptide
- Sequence / structure
- 28-mer vasoactive intestinal peptide
Mechanism
VPAC1/VPAC2 agonist with broad anti-inflammatory and smooth-muscle relaxant effects. Very short half-life limits systemic use — infusion and topical delivery research emphasized.
Studies & clinical programs
Pulmonary hypertension models
Published research models
- Peer-reviewed literature documents endpoints under Pulmonary hypertension models experimental designs.
Autoimmune disease adjunct research
Published research models
- Peer-reviewed literature documents endpoints under Autoimmune disease adjunct research experimental designs.
Research models in literature
- Pulmonary hypertension models
- Autoimmune disease adjunct research
Literature highlights
- VPAC1/VPAC2 agonist studied in pulmonary hypertension and autoimmune adjunct models.
- Broad anti-inflammatory and smooth-muscle relaxant effects in organ-bath pharmacology.
- Very short plasma half-life — infusion and topical delivery research emphasized.
Combination research notes
Immune-modulation research references VIP alongside thymosin alpha-1 and LL-37.
Key targets & pathways
Research areas
Routes in research literature
Also known as
Stability & storage phases
| Phase | Condition | Guidance |
|---|---|---|
| Lyophilized | Sealed vial, refrigerated (2–8 °C) | Intact lyophilized cake or powder is typically stable for months to years per published stability data; protect from moisture, light, and repeated freeze-thaw of the dry vial. |
| Reconstituted | Bacteriostatic water (0.9% benzyl alcohol), refrigerated | Most aqueous peptide solutions remain usable for approximately 2–4 weeks refrigerated; verify published stability data and label with reconstitution date. |
| Working aliquots | Pre-drawn syringes or microtubes, frozen (−20 °C) | Aliquot promptly after mixing to limit freeze-thaw cycles on the main vial; thaw once and use to reduce protease-mediated degradation. |
Stability windows are formulation-dependent — verify published data and your lab SOP.
Reconstitution reference table
| Vial (mg) | Diluent (mL) | mcg/mL | Units @ 100 mcg | Units @ 250 mcg | Units @ 500 mcg |
|---|---|---|---|---|---|
| 5 | 2 | 2500.0 | 4 | 10 | 20 |
| 10 | 2 | 5000.0 | 2 | 5 | 10 |
U-100 insulin syringe scale (100 units = 1 mL). Illustrative only — not dosing guidance.
Reconstitution steps
- Allow vial to reach room temperature (15–30 min)
- Swab rubber stopper with alcohol prep pad
- Draw calculated bacteriostatic water into syringe
- Inject diluent slowly down vial wall — do not spray directly onto cake
- Gently swirl until fully dissolved — do not shake vigorously
- Label with date, concentration, and diluent volume
- Refrigerate and use within your lab stability window
Typically reconstituted with 1–2 mL bacteriostatic water.
Laboratory record checklist
- Compound identity recorded in lab notebook (name, lot, preparation date)
- Analytical identity cross-checked against published sequence or structure
- Potency or concentration documented from analytical certificate when available
- Purity or HPLC data filed when provided with research material
- Appearance noted: intact lyophilized cake or uniform powder
- Sterility / endotoxin report archived when available
- Storage temperature applied immediately per published stability guidance